The observation that the FASN blockade leads to apoptosis in HER2+ BC cells has led to preclinical investigations using the dual FASN and HER2 signaling blockade in BC models resistant to anti-HER2 drugs [214]. This evidence concerns the gene ERBB2 and breast cancer.